BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Autoimmunity
,
Prozac
,
rs2476601
,
ZBTB7A
,
Coagulation
,
Ischemia
,
Pancreas
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Sutent
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Screening of FDA-approved drugs identifies sutent as a modulator of UCP1 expression in brown adipose…
Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.
Adverse effects of Sutent(®): pseudoporphyria and scrotal necrosis].
Effect of sutent and celecoxib on the properties of endothelial cells in vitro].
Sunitinib Treatment-elicited Distinct Tumor Microenvironment Dramatically Compensated the Reduction …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
Temodar and Sutent as Therapy for Melanoma
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ